Used in targeted cancer therapy, particularly for epithelial-derived tumors such as bladder, breast, and colorectal cancers. Binds specifically to EpCAM (CD326), a protein overexpressed on cancer cells, enabling direct delivery of therapeutic agents or facilitating immune-mediated cell destruction. Investigated in clinical trials for non-muscle invasive bladder cancer (NMIBC) as a recombinant protein therapeutic to reduce tumor recurrence after surgery. Also serves as a key component in the development of antibody-drug conjugates (ADCs) and diagnostic tools for detecting circulating tumor cells. Its high specificity makes it valuable for both treatment and monitoring of epithelial cancers.